Analysis of more than 500,000 cells, including those from acute myeloid leukemia (AML) patients and healthy controls, has led to the identification of potential CAR-T cell targets like CSF1R and CD86 (44). This evidence concerns the gene CD86 and acute myeloid leukemia.